FGFR2 and cholangiocarcinoma: The FIGHT-202 trial (Phase II, multicenter, open-label) demonstrated the antitumor efficacy of pemigatinib in previously treated patients with FGFR2 fusion or rearrangement–positive cholangiocarcinoma.